33256258|t|Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?
33256258|a|The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences of COVID-19 infections has been advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, and immunomodulatory compound, melatonin could be unique in impairing the consequences of SARS-CoV-2 infection. Moreover, indirect evidence points out to a possible antiviral action of melatonin by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also an effective chronobiotic agent to reverse the circadian disruption of social isolation and to control delirium in severely affected patients. As a cytoprotector, melatonin serves to combat several comorbidities such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases, which aggravate COVID-19 disease. In view of evidence on the occurrence of neurological sequels in COVID-19-infected patients, another putative application of melatonin emerges based on its neuroprotective properties. Since melatonin is an effective means to control cognitive decay in minimal cognitive impairment, its therapeutic significance for the neurological sequels of SARS-CoV-2 infection should be considered. Finally, yet importantly, exogenous melatonin can be an adjuvant capable of augmenting the efficacy of anti-SARS-CoV-2 vaccines. We discuss in this review the experimental evidence suggesting that melatonin is a potential "silver bullet" in the COVID 19 pandemic.
33256258	4	13	Melatonin	Chemical	MESH:D008550
33256258	57	65	COVID-19	Disease	MESH:D000086382
33256258	66	74	Patients	Species	9606
33256258	105	114	melatonin	Chemical	MESH:D008550
33256258	188	207	COVID-19 infections	Disease	MESH:D000086382
33256258	288	300	inflammatory	Disease	MESH:D007249
33256258	333	342	melatonin	Chemical	MESH:D008550
33256258	392	412	SARS-CoV-2 infection	Disease	MESH:D000086382
33256258	487	496	melatonin	Chemical	MESH:D008550
33256258	517	527	SARS-CoV-2	Species	2697049
33256258	528	559	angiotensin-converting enzyme 2	Gene	59272
33256258	573	582	Melatonin	Chemical	MESH:D008550
33256258	694	702	delirium	Disease	MESH:D003693
33256258	724	732	patients	Species	9606
33256258	754	763	melatonin	Chemical	MESH:D008550
33256258	811	819	diabetes	Disease	MESH:D003920
33256258	821	839	metabolic syndrome	Disease	MESH:D024821
33256258	845	894	ischemic and non-ischemic cardiovascular diseases	Disease	MESH:D017202
33256258	912	928	COVID-19 disease	Disease	MESH:D000086382
33256258	971	991	neurological sequels	Disease	MESH:D009461
33256258	995	1012	COVID-19-infected	Disease	MESH:D000086382
33256258	1013	1021	patients	Species	9606
33256258	1055	1064	melatonin	Chemical	MESH:D008550
33256258	1120	1129	melatonin	Chemical	MESH:D008550
33256258	1163	1178	cognitive decay	Disease	MESH:D003731
33256258	1190	1210	cognitive impairment	Disease	MESH:D003072
33256258	1249	1269	neurological sequels	Disease	MESH:D009461
33256258	1273	1293	SARS-CoV-2 infection	Disease	MESH:D000086382
33256258	1352	1361	melatonin	Chemical	MESH:D008550
33256258	1424	1434	SARS-CoV-2	Species	2697049
33256258	1513	1522	melatonin	Chemical	MESH:D008550
33256258	1561	1569	COVID 19	Disease	MESH:D000086382
33256258	Negative_Correlation	MESH:D008550	MESH:D003920
33256258	Negative_Correlation	MESH:D008550	MESH:D017202
33256258	Negative_Correlation	MESH:D008550	MESH:D009461
33256258	Negative_Correlation	MESH:D008550	MESH:D024821
33256258	Negative_Correlation	MESH:D008550	MESH:D007249
33256258	Negative_Correlation	MESH:D008550	MESH:D003072
33256258	Negative_Correlation	MESH:D008550	MESH:D000086382
33256258	Negative_Correlation	MESH:D008550	MESH:D003693
33256258	Association	MESH:D008550	59272
33256258	Negative_Correlation	MESH:D008550	MESH:D003731

